A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
This is a phase 2 clinical trial to evaluate the safety and efficacy of duvelisib as a
monotherapy in subjects diagnosed with follicular lymphoma (FL) that is relapsed or
refractory to either chemotherapy or radioimmunotherapy (RIT).